Table 1.
Baseline Characteristics of the Study Population (n = 44).
| Characteristics | Valuea, n (%) | |
|---|---|---|
| Age, years, median [range] | 68 [31–83] | |
| Sex (male) | 31 (70.5%) | |
| ECOG PS at time of pembrolizumab monotherapyb | ||
| 0 | 31 (70.5%) | |
| 1 | 10 (22.7%) | |
| 2 | 3 (6.8%) | |
| Smoking status | ||
| Current smoker or ever smoked | 35 (79.5%) | |
| Never smoked | 9 (20.4%) | |
| Pathological subtype | ||
| Squamous cell carcinoma | 17 (38.6%) | |
| Non-squamous NSCLC | 27 (61.4%) | |
| PD-L1 expression | ||
| ≥ 50% (high) | 27 (61.4%) | |
| 1–49% (low) | 17 (38.6%) | |
| EGFR status in non-squamous NSCLC | ||
| Mutant | 3 (6.8%) | |
| Number of prior chemotherapy regimens | ||
| 0 | 22 (50%) | |
| 1 | 13 (29.5%) | |
| ≥ 2 | 9 (20.5%) | |
| Development of irAEs | 31 (70.5%) | |
| Development of severe irAEs | 10 (22.7%) | |
| Onset of irAEs, weeks, median [range] | 3.3 [0–28] | |
ECOG, Eastern Cooperative Oncology Group; irAE, immune related adverse event; PS, performance-status; NSCLC, non-small-cell lung cancer; PD-L1, programmed death ligand-1; EGFR, epidermal growth factor receptor; n, number
aValues in the table are presented as the median with the range given in square brackets or as a number with the percentage in parentheses.
bEastern Cooperative Oncology Group performance status (ECOG PS) scores range from 0 to 4, with high numbers indicating high disability.